Partnerships with Strong, Established Companies
THC has a number of medicinal cannabis partnerships. It’s commercial partners are all revenue positive with solid IP portfolios and provide market access to 3 continents.
Our constantly growing list of Australian research partners comprises well-respected medical research institutions that display a proven track record of success.
Distribution Agreement with Endoca – EUROPE
- A recognised leader in the supply of high quality CBD products worldwide.
- European pioneers in extraction and purification, sales exceeding 50 million Euro per annum.
- Focus on distributing world’s best medicinal cannabis products in Australia.
- CBD oil, CBD capsules and a unique CBD+CBDA oil.
Strategic Alliance with BOL Pharma – ISRAEL
- One of Israel’s leading suppliers of medicinal cannabis solutions with an extensive portfolio of products targeted for specific clinical applications
- Pioneering creation of medicinal cannabis industry in Israel since 2007
- Partnership to develop Australian market through THC
- Supplying products for Clinical Trials
Strategic Partnership with Sinapse and Pharma Programs –Australia
- Sinapse has extensive experience working for, and with, global pharmaceutical companies
- They offer broad experience and deep expertise in key areas such as strategy formulation, business transformation, systems selection and implementation
- Pharma Programs works closely with doctors, pharmacists and industry to provide bespoke solutions to support optimal medication usage, adherence and ultimately health outcomes. Their solutions improve access to pharmaceutical treatments and programs for all stakeholders.
- Together, Sinapse and Pharma Programs administer the Medicinal Cannabis Medicines Portal (MCMP) http://mcmp.com.au/
- The MCMP is a collaborative approach between Prescribers, Pharmacists and Suppliers to help patients get timely access to appropriate Medicinal Cannabis treatment.
Strategic Partnership with ANSPEC
- For 25 years, Anspec has been a major supplier of medical and pharmaceutical products to the Pacific region and has maintained long close relations with Government and private health care centres, together with retail pharmacy clients.
- Endoca products will be distributed in Australia by Anspec, which will offer accounts to participating pharmacies
Foundation member of MCIA
- MCIA represents licensed companies undertaking medicinal cannabis research, cultivation and manufacturing in Australia. It will be a responsible steward of the industry and a credible reference for policy-makers.
- Australia has the opportunity to forge a thriving domestic medicinal cannabis industry, with products that are trusted by patients and their prescribers. The association seeks to operate with high standards of quality, delivered within appropriate nationally-harmonised, policy and regulatory frameworks.
- MCIA seeks to be an industry with a strong export focus, producing trusted products for a global market.